Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.85 |
| ▸ | PTPN11 | Q06124 | 9/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | USP2 | O75604 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280796 | 0.90 | PTPN11 (1.00) | TP53PTPN11ALDH1A1TSHRHTT | |
| SCHEMBL12372326 | 0.87 | PTPN11 (0.83) | TP53PTPN11ALDH1A1KDM4EPOLB | |
| SCHEMBL12372385 | 0.86 | PTPN11 (0.77) | TP53PTPN11ALDH1A1TSHRUSP2 | |
| SCHEMBL12372379 | 0.85 | PTPN11 (0.82) | TP53PTPN11ALDH1A1KDM4EPOLB | |
| SCHEMBL12372370 | 0.85 | PTPN11 (0.83) | TP53PTPN11ALDH1A1KDM4EPOLB | |
| SCHEMBL12372346 | 0.82 | PTPN11 (0.84) | PTPN11ALDH1A1TSHRUSP2KDM4E | |
| SCHEMBL2275960 | 0.82 | PTPN11 (1.00) | PTPN11 | |
| SCHEMBL12372317 | 0.81 | PTPN11 (0.85) | TP53PTPN11ALDH1A1TSHRUSP2 | |
| SCHEMBL12372368 | 0.81 | PTPN11 (0.84) | PTPN11ALDH1A1KDM4EPOLBPTPN7 | |
| SCHEMBL12372348 | 0.81 | PTPN11 (0.82) | PTPN11ALDH1A1TSHRUSP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | PTPN7, PTPN3, PTPN5 | TP53 124/4885PTPN11 16/4885ALDH1A1 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.